The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company using the microbiome to detect early-stage cancer, Micronoma has a cutting-edge advantage, and is developing this method using minimally invasive blood samples.
Oncobiota™ Platform Overview
Start with as little as 400ul of plasma
Micronoma Sample Prep
Extract nucleic acid, prepare NGS library prep and controls for maximum contamination elimination (noise reduction)
NGS on Existing Platforms
Generate NGS shotgun data with proprietary analysis methods – 6 patents filed
Cancer/Non Cancer Likelihood Report
Provide actionable results with clinically relevant performances. Lung cancer example:
– Sensitivity (88%)
– Specificity (93%)
Our Oncobiota™ platform reveals the cancer-related microbiome with unparalleled specificity and sensitivity.
Our minimally invasive and precise microbiome-driven liquid biopsy™ method can detect cancer even in its earliest stages, unlike tests that only focus on the human genome, epigenome, or cancer mutations, which rely on the size of a tumor to be large enough to generate enough circulating biomarkers. Micronoma’s method, analysing a multitude of circulating microbial markers linked to the tumor tissue as well as the host response to the cancer, seems to have an advantage in early stage.
Oncobiota™ can be applied to many cancer types. Starting with lung cancer, which has the highest need for early detection and with one of the highest incidence and mortality rates, we can make a big difference in the lives of the many patients affected each year. In addition, current standard of care for lung cancer detection (low dose CT scan) is plagued with a very high rate of false positives (95%+), leading to unnecessary lung tissue biopsies. With a lower rate of false positives, the Micronoma platform has the opportunity to significantly reduce the risk and cost of lung cancer diagnosis.
Advantages Over Traditional Liquid Biopsy
A liquid biopsy is a test done on a sample of blood to look for a methylation or fragmentation profile and/or within circulating tumor cells (CTC) and/or DNA that is shed from the tumor.
However, to detect these signals, a large enough tumor mass is required, which prevents the reliable possibility of accurate cancer detection in its earliest stages.
At Micronoma, we focus on the circulating microbial nucleic acid signatures present from the tumor and the body’s response to the developing tumor. Importantly, these signals are not dependent on tumor size, enabling our proprietary platform to detect cancer at an earlier stage of development.
Humans and Microbes
Humans and microbes co-exist in a mutually beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues, and blood, even when we are healthy.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa, and viruses—that live on and inside the human body. The composition of the microbiome changes with many factors such as location in the body, lifestyle, and gender. If analyzed properly, the microbiome can reveal the status of our health.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues and blood. Micronoma’s proprietary platform and global expertise allow for the identification of microbial signatures in circulating blood that are predictive of a cancerous tumor. This minimally invasive liquid biopsy sample type can be more easily collected than a solid tissue sample.
draw to collect samples
research, discovery, and
NEXT GEN SEQUENCING
Using genomic sequencing to
pipelines to decipher and